Get Real Health’s Patient Engagement Platform Ranked Number One by Chilmark Research

Chilmark Research recently named Get Real Health’s InstantPHR® the top ranked patient engagement platform in the industry. The independent global research and advisory firm that evaluates healthcare IT solutions gave InstantPHR® an overall grade of “A-,” the highest among the top 14 products on the market. The report stated that Get Real Health was “the product standout” with its “highly configurable platform and product vision, and understanding of end-user needs.”

Chilmark Research graded the 14 patient engagement technologies based on their product capabilities, including functionality, usability and operational utility, as well as market vision and market execution. Get Real Health received a grade of “A-” for its product capabilities and a “B+” for its market capabilities for the overall grade of “A-.” This was the highest grade among the 14 competitors, which included Allscripts, Cerner and WebMD.

Increasingly, patient engagement is a major factor in helping healthcare organizations improve health outcomes while cutting costs. Get Real Health, the report noted, is one of the only products available on the market today that focuses on long-term success by giving patients and providers “a complete engagement offering” that goes “beyond standard VDT [view, download, transmit] and communication features” mandated by the federal government as part of Meaningful Use (MU) requirements.

“InstantPHR® is helping healthcare organizations around the world accomplish their patient engagement goals, including enabling U.S. organizations to not just meet but exceed MU requirements,” said Robin Wiener, president and founding partner of Get Real Health. “By meeting these requirements, hospitals and healthcare providers are earning millions of dollars in incentives—making it a true win-win for everyone involved.”

As Chilmark researchers stated in the report,“[P]olicymakers and thought leaders are scrutinizing a paternalistic tradition of healthcare delivery that needs to be updated if goals for reform and cost containment are to be realized. Alongside this shift, advances in personal technology and consumer convenience are reshaping expectations for the patient-provider relationship.” To this end, Get Real Health’s InstantPHR® offers healthcare organizations a highly adaptable portal that connects provider-generated data from one or more clinical systems with patient-generated data entered via the web portal, mobile apps, or any one of the hundreds of connected health devices.

“The power of the platform is its ability to pull together all this separate data to deliver a personalized experience to patients, while providing a more holistic view of a patient’s health,” said Wiener. “Armed with this comprehensive data, care teams can make informed decisions resulting in better health outcomes.”

About Get Real Health 
Rockville, Maryland-based Get Real Health specializes in providing an untethered PHR solution at a system-wide level to healthcare organizations, non-profits and governments around the world. Our award-winning product — InstantPHR® — is a bidirectional data sharing patient engagement platform with tools that empower patients to be an active part of their care team. We help organizations meet both current and future needs such as chronic disease management, mobile strategies, remote patient monitoring, wellness, as well as Meaningful Use 1, 2, 3 and beyond. Get Real Health has strategic partnerships with industry leaders including Orion Health, TELUS Health Solutions, Caradigm, Telstra Health, Microsoft, and HumanAPI. Visit: http://www.getrealhealth.com, or watch a two-minute video at http://vimeo.com/86727501 to learn more.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.